136 related articles for article (PubMed ID: 35569476)
21. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
[TBL] [Abstract][Full Text] [Related]
23. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
[No Abstract] [Full Text] [Related]
24. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
[TBL] [Abstract][Full Text] [Related]
25. Bicalutamide treatment for locally advanced prostate cancer.
Anderson J
Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
[TBL] [Abstract][Full Text] [Related]
26. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
Brawer MK
BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893
[No Abstract] [Full Text] [Related]
27. Bicalutamide causes heart failure in an elderly patient with prostate cancer.
Guirguis K
Expert Opin Drug Saf; 2016; 15(3):297-302. PubMed ID: 26745594
[TBL] [Abstract][Full Text] [Related]
28. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A
Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605
[TBL] [Abstract][Full Text] [Related]
29. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
Sternberg CN
BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
[No Abstract] [Full Text] [Related]
30. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
31. Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Taneja SS
J Urol; 2013 Sep; 190(3):880. PubMed ID: 23931194
[No Abstract] [Full Text] [Related]
32. The third analysis of the bicalutamide Early Prostate Cancer programme.
Iversen P;
BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
[No Abstract] [Full Text] [Related]
33. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
[No Abstract] [Full Text] [Related]
34. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
[TBL] [Abstract][Full Text] [Related]
35. Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.
Motofei IG; Rowland DL; Popa F; Kreienkamp D; Paunica S
BJU Int; 2011 Jul; 108(1):110-5. PubMed ID: 20955264
[TBL] [Abstract][Full Text] [Related]
36. [The role of bicalutamide in the treatment of prostate cancer].
Stav SY; Segal G
Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
[TBL] [Abstract][Full Text] [Related]
37. The role of anti-androgen monotherapy in the treatment of prostate cancer.
Bishop M
BJU Int; 2003 Oct; 92(6):653-4. PubMed ID: 14511060
[No Abstract] [Full Text] [Related]
38. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
McPartlin AJ; Glicksman R; Pintilie M; Tsuji D; Mok G; Bayley A; Chung P; Bristow RG; Gospodarowicz MK; Catton CN; Milosevic M; Warde PR
Cancer; 2016 Aug; 122(16):2595-603. PubMed ID: 27219522
[TBL] [Abstract][Full Text] [Related]
39. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
Nadal R; McMahan ZH; Antonarakis ES
Clin Genitourin Cancer; 2013 Dec; 11(4):e15-23. PubMed ID: 23820064
[No Abstract] [Full Text] [Related]
40. [Incorrect about hormone treatment in prostatic cancer].
Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
